Bessemer Group’s Beam Therapeutics BEAM Stock Holding History

Bessemer Group’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-35	Closed	-$1K	–	2468
2024 Q3	$1K	Buy	+35	New	+$904	﹤0.01%	2343

Other funds holding BEAM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Bessemer Group's BEAM Position: Q4 2024 in Review

Bessemer Group sold out of Beam Therapeutics (BEAM) in Q4 2024, closing a stake of 35 shares — an estimated $1K sold.

Bessemer Group first reported a position in BEAM in Q3 2024 and held it in 1 quarter. The position peaked at $1K in Q3 2024. 231 funds tracked by Wall St. Rank hold BEAM as of Q4 2024.

Bessemer Group reported no remaining Beam Therapeutics position as of Q4 2024 after selling out during the quarter.
Bessemer Group sold 35 Beam Therapeutics shares in Q4 2024, an estimated $1K.
Bessemer Group first reported a position in Beam Therapeutics in Q3 2024 and held it in 1 quarter.
Bessemer Group's Beam Therapeutics position peaked at $1K in Q3 2024.
231 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2024.

Based on Bessemer Group's 13F filing for Q4 2024, filed 13 Feb 2025.